RBCC Scouts New Biotech Innovations at NIBA Investment Conference

  RBCC Scouts New Biotech Innovations at NIBA Investment Conference  NIBA Investment Conference 2012  Business Wire  NOKOMIS, Fla. -- November 14, 2012  Rainbow Coral Corp. (OTCBB: RBCC) executives will be on hand this week at the 124^th National Investment Banking Association (NIBA) Investment Conference in Las Vegas to seek out new partnership opportunities in the red-hot biotechnology sector.  The conference offers a chance for public and private companies to make formal presentations to corporations such as RBCC biotech subsidiary Rainbow Biosciences that are interested in new innovations ripe for capital investment.  “We’re particularly interested in discovering additional projects that exhibit short paths to marketability,” said RBCC CEO Patrick Brown. “We look forward to networking with hungry entrepreneurs and emerging businesses with the potential to grow our base of assets and increase shareholder value.”  RBCC is already hard at work helping to bring incredible new healthcare technologies to new markets. The company’s joint venture partner, Nano3D BioSciences (n3D) has developed a revolutionary 3D cell-culturing system that could soon lead to a breakthrough in cancer research. RBCC has also finalized joint venture terms with Amarantus BioSciences (OTCBB: AMBS), makers of a ground-breaking new blood-test diagnostic for Parkinson’s disease.  The company hopes to add to its portfolio of projects for commercialization at this week’s NIBA conference.  Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ:AMGN),Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott Laboratories (NYSE:ABT).  For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.  Follow us on Twitter atwww.twitter.com/RBCCinfo.  About Rainbow BioSciences  Rainbow BioSciences is a division ofRainbow Coral Corp.(OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website atwww.rainbowbiosciences.com. For investment information and performance data on the company, please visitwww.RainbowBioSciences.com/investors.  Notice Regarding Forward-Looking Statements  Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.  Contact:  Rainbow Coral Corp. Patrick Brown, 813-367-9511 President and CEO info@rainbowcoral.com  
Press spacebar to pause and continue. Press esc to stop.